Future Business Development

Sartorius Stedim Biotech plans to grow profitably in 2021 as well. Consolidated sales revenue is thus projected to increase by about 20% to 26%. Initial consolidation of the acquisitions is expected to contribute about 5.5 percentage points to this growth, and the impact of the pandemic-related businesses on Group revenue, which is difficult to precisely estimate at present, could amount to up to 7 percentage points.

Regarding profitability, the company forecasts that its underlying EBITDA margin will be about 32.0%, up from 31.7% a year earlier, with a negligible impact of the acquisitions on profitability.

Due to very high organic growth, Sartorius Stedim Biotech is moving the expansion of production capacities and its digital infrastructure ahead of schedule. As a result, the CAPEX ratio is expected to be around 15% (previous year: 8.3%).

In view of the Group's financial situation, management projects a slight decrease in the ratio of net debt to underlying EBITDA to around 0.75 as of the end of fiscal 2021 (previous year: 0.8). This projection does not include any potential acquisitions.

All forecasts are based on constant currencies, as in the past years. In addition, the company assumes that the global economy will increasingly recover as the current year progresses and that supply chains will remain stable.